CAR T cell therapy in autoantibody-mediated neurological disorders: a promising strategy
Muzi Wen1,2, Ruoyi Zheng1,2, Hanqing Zhang3
1Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou Road North 1838#, Guangzhou, 510515, China.
Journal of Neuroinflammation
|March 13, 2026
Abstract
No abstract available in PubMed .
Keywords:
Anti-NMDA receptor encephalitisAutoantibody-mediated neurological disordersCAR T cell therapyDiacylglycerol lipase alpha antibody associated encephalitisLambert-Eaton myasthenic syndromeMOG antibody-associated diseaseMultiple sclerosisMyasthenia gravisNeuromyelitis optica spectrum disorderStiff person syndromeMore Related Videos
Related Concept Videos
Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Autoimmune Disorders
2.1K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
2.1K
Myasthenia Gravis: Overview and Treatment
3.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.3K


